Remove 2019 Remove Stent Remove Thrombosis
article thumbnail

Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial

Circulation

Background:Stopping aspirin within 1 month after implantation of a drug-eluting stent (DES) for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome (ACS). Circulation, Ahead of Print. versus 3.4%; HR, 0.35 [95% CI, 0.20–0.61];P<0.001).Conclusions:This 0.61];P<0.001).Conclusions:This

Stent 40
article thumbnail

Systematic approach to obtain axillary arterial access for pediatric heart catheterizations

Frontiers in Cardiovascular Medicine

Methods We retrospectively reviewed children with congenital heart diseases (CHDs) who received trans-axillary arterial catheterizations between January 2019 and February 2023. Overall, 27/36 procedures were interventional, including 6 aortic valvuloplasties, 6 balloon angioplasties, and 15 stenting procedures. months (IQR, 0.3–5.4),

article thumbnail

Concerning EKG with a Non-obstructive angiogram. What happened?

Dr. Smith's ECG Blog

The commonest causes of MINOCA include: atherosclerotic causes such as plaque rupture or erosion with spontaneous thrombolysis, and non-atherosclerotic causes such as coronary vasospasm (sometimes called variant angina or Prinzmetal's angina), coronary embolism or thrombosis, possibly microvascular dysfunction.

Plaque 127
article thumbnail

From the Member Sections | Tackling the Polypharmacy Pandemic in CV Care

American College of Cardiology

7 The use of antiplatelet agents to prevent stent thrombosis, moderate- to high-dose statin therapy after acute coronary syndromes, or antihypertensive agents in asymptomatic patients may all be perceived by patients as not providing benefit because they may not feel the effects.8

article thumbnail

Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial

Circulation

The primary efficacy objective was to demonstrate superiority of PPA to reduce the primary efficacy end point of all-cause death, nonfatal myocardial infarction, nonfatal stroke, stent thrombosis (definite), or urgent revascularization (any vessel) within 30 days. to 1.57]).

article thumbnail

Something Winter This Way Comes

EMS 12-Lead

A second 12 Lead ECG was recorded: This is a testament to the dynamic nature of coronary thrombosis and thrombolysis. One stent was deployed with restorative TIMI-0 flow. The patient verbalized spontaneous improvement just before 324mg ASA administration. But the lesion is still active! However, when the Troponin I returned 8.4

STEMI 52
article thumbnail

Hypertrophic Cardiomyopathy

EMS 12-Lead

A mid-LAD culprit lesion was identified and stented. Cardiology felt her chest pain to be, most likely, the result of coronary supply-demand mismatch in the context of HCM endothelial remodeling (i.e. Type II MI), however decided to pursue coronary angiogram out of an abundance of caution. References Naidu, S. American College of Cardiology.